Profund Advisors LLC Grows Stake in Denali Therapeutics Inc. $DNLI

Profund Advisors LLC boosted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 78.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 71,634 shares of the company’s stock after acquiring an additional 31,478 shares during the quarter. Profund Advisors LLC’s holdings in Denali Therapeutics were worth $1,183,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Denali Therapeutics by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after purchasing an additional 3,432 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Denali Therapeutics by 58.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after purchasing an additional 614,555 shares during the period. Empowered Funds LLC boosted its holdings in shares of Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after buying an additional 2,052 shares during the last quarter. Woodline Partners LP grew its position in Denali Therapeutics by 13.5% during the first quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock valued at $1,543,000 after buying an additional 13,517 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Denali Therapeutics by 1.7% during the second quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock valued at $2,681,000 after buying an additional 3,210 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

NASDAQ DNLI opened at $18.83 on Thursday. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 12 month low of $12.58 and a 12 month high of $23.77. The stock has a market cap of $2.99 billion, a price-to-earnings ratio of -6.54 and a beta of 0.99. The company’s 50 day moving average is $19.88 and its two-hundred day moving average is $19.03.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter in the prior year, the business earned ($0.78) earnings per share. As a group, research analysts anticipate that Denali Therapeutics Inc. will post -2.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DNLI has been the topic of several recent research reports. Morgan Stanley decreased their price target on shares of Denali Therapeutics from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Wedbush cut their price objective on shares of Denali Therapeutics from $25.00 to $23.00 and set an “outperform” rating for the company in a research report on Friday, May 8th. Stifel Nicolaus upped their price objective on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. BTIG Research reaffirmed a “buy” rating and issued a $39.00 target price on shares of Denali Therapeutics in a report on Monday, May 11th. Finally, Robert W. Baird lifted their target price on Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.